Epidermal growth factor receptor mutations

Details Epidermal growth factor receptor mutations Epidermal growth factor receptor mutations

2011-07-19

2011-07-19

Allen, Marianne P (Department: 1647)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

Reexamination Certificate

active

07981605

ABSTRACT:
Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3′-kinase (“Pl3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant Pl3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described.

REFERENCES:
patent: 7294468 (2007-11-01), Bell et al.
patent: 7560111 (2009-07-01), Kao et al.
patent: 2005/0272083 (2005-12-01), Seshagiri
patent: 2008/0306054 (2008-12-01), Chessari et al.
patent: WO 91/03489 (1991-03-01), None
patent: WO 01/68711 (2001-09-01), None
patent: WO 2007/001868 (2007-01-01), None
Pao et al PLOS medicine, Mar. 2005, vol. 2, issue 3, pp. 225236, published Feb. 22, 2005.
Doody et al., Mol Cancer Ther, 6(10):2642-2651, Oct. 2007.
Blencke et al., Chemistry & Biology, 11:691-701, May 2004.
Blencke et al., Journal of Biological Chemistry, 278(17):15435-15440, 2003.
Pallis et al., European Journal of Chemistry, 45:2473-2487, 2009.
Herbst et al., Clinical Lung Cancer, 6(Supplement 1): S7-S19, Dec. 2004.
Thomas et al., Cold Spring Harbor Symposia on Quantitiative Biology, LXX: 73-81, 2005.
Allison, “Is personalized medicine finally arriving?”Nat. Biotech., 26: 509-517 (2008).
Amler et al., “Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors,”Cold Spring Harbor Symp. Quant.Biol., 70: 483-488 (2005).
Baselga et al., “Determinants ofRASistance to anti-epidermal growth factor receptor agents,”J. Clin. Oncol., 26: 1582-1584 (2008).
Eberhard et al., “Correlation of mutations in EGFR with clinical outcomes in NSCLC patients treated with erlotinib,”EJC Supplements, Proceedings of the 16thEORTC-NCI-AACRSymposium on Molecular Targets and Cancer Therapeutics, 2: 124 (2004).
Eberhard et al., “Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib,”Lung Cancer, 49:S62 (2005).
Finocchiaro et al., “EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer,”ASCO, Abstract No. 4021 (2007).
Moroni et al., “Gene copy of number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study,”Lancet Oncol., 6: 279-286 (2005).
Moroni et al. “Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer,”Ann. Onc., 16: 1848-1849 (2005).
Sartore-Bianchi et al., “Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer,”Ann. Onc., 17(suppl. 2): ii49-ii51 (2006).
PCT Notification Concerning Transmittal of International Preliminary Report on Patentability, International Preliminary Report on Patentability, and Written Opinion of the International Searching Authority, mailed Sep. 7, 2007, for International Application No. PCT/US2006/006751.
Barber et al., “Somatic mutations ofEGFRin colorectal cancers and glioblastomas,”N. Engl. J. Med, 351:2883 (2004).
Eberhard et al., “Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib,”J. of Clin. Oncol., 23:5900-5909 (2005).
Gandara et al., “Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?”J. of Clin. Oncol., 23:5856-5858 (2005).
Hirsh et al., “Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer,”Curr. Opin. Oncol., 17:118-122 (2005).
Hirsh et al., “Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis,”J. of Clin. Oncol., 21: 3798-3807 (2003).
Kobayashi et al., “EGFRmutation and resistance of non-small-cell lung cancer to gefitinib,”N. Engl. J. Med., 352:786-792 (2005).
Lynch et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,”N. Engl. J. Med., 350:2129-2139 (2004).
Lynch et al., “A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC),”J. of Clin. Oncol., 2004 ASCO Ann. Meeting Proc., 22(14S):7084 (2004).
Paez et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,”Science, 304:1497-1500 (2004).
Pao et al., “EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib,”PNAS, 101: 13306-13311 (2004).
Stephens et al., “Intragenic ERBB2 kinase mutations in tumours,”Nature, 431:525-526 (2004).
Wang et al., “Prevalence of somatic alterations in the colorectal cancer cell genome,”PNAS, 99:3076-3080 (2002).
Gazdar et al., “Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?”Trends in Molecular Medicine, 10:481-486 (2004).
Huang et al., “High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan,”Clin. Cancer Res., 10: 8195-8203 (2004).
Marchetti et al., “EGFRmutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment,”Journal of Clinical Oncology, 23: 857-865 (2005).
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration mailed Nov. 27, 2006, in International Application No. PCT/US2006/006751.
Herbst, “Review of Epidermal Growth Factor Receptor Biology,”Int. J. Radiation Oncology Biol. Phys., 59(2) Supp.: 21-26 (2004).
Snyder et al., “Overview of Monoclonal Antibodies and Small Molecules Targeting the Epidermal Growth Factor Receptor Pathway in Colorectal Cancer,”Clinical Colorectal Cancer, 5(Supp. 2): S71-S80 (2005).
Rama Krishna Kancha, et al., Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy, Clin. Cancer. Res. 15 (2) 460-467 (Jan. 15, 2009).
Freeman et al, “Activity of Panitumumab Alone or With Chemotherapy in Non-Small Cell Lung Carcinoma Cell Lines Expressing Mutant Epidermal Growth Factor Receptor”;Mol. Cancer Ther.2009;8(6).
Argeta,“Epidermal Growth Factor Receptor Dependence in Human Tumors: More than just Expression?”,The Oncologist; 2002; V.7 Suppl. 4, 31-39.
Roskoski, “The ErbB/HER receptor protein-tyrosine kinases and cancer”Biochemical and Biophysical Research Communications; 2004; V.319, 1-11.
Saito et al. “Differential Activation of Epidermal Growth Factor (EGF) Receptor Downstream Signaling Pathways by Betacellulin and EGF”Endocrinology; 2004; V.145 (9), 4232-4243.
Torring et al. “Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study”BJU International, 2002; V.89, 583-390.
Witton et al. “Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer”Journal of Pathology; 2003; V.200, 290-297.

Affiliated with

Also associated with

Rating

Epidermal growth factor receptor mutations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Epidermal growth factor receptor mutations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epidermal growth factor receptor mutations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2727111